REGENXBIO shares 2-year data on gene therapy injection for wet AMD
Pipeline

REGENXBIO shares 2-year data on gene therapy injection for wet AMD

Dose-escalation study reports stable or improved vision and retinal anatomy up to 2 years.
Study links pandemic-induced psychosocial functions to visual impairment
Research

Study links pandemic-induced psychosocial functions to visual impairment

Vision impairment could be a potential risk factor for psychosocial dysfunction and social isolation.
Florida ODs kill yet another not-a-doctor bill
Legal

Florida ODs kill yet another not-a-doctor bill

Just 9 months after the governor’s veto of S.B. 230, legislators failed to continue the state’s ongoing ‘eyeball wars.’
Foundation Fighting Blindness partners with BlueRock Therapeutics on IRD study
Research

Foundation Fighting Blindness partners with BlueRock Therapeutics on IRD study

Collaboration will add a new cohort to the nonprofit’s Uni-Rare natural history study.
EHR-based reminders may bring back no-show patients
Research

EHR-based reminders may bring back no-show patients

Clinical trial investigates the relationship between electronic reminders and patient re-engagement.
Eye safety tips you need to know ahead of the solar eclipse
Events

Eye safety tips you need to know ahead of the solar eclipse

Leading eyecare organizations and clinical experts offer their professional advice for safely watching this year’s big event on April 8.
Astellas receives permanent J-code for IZERVAY
Products

Astellas receives permanent J-code for IZERVAY

FDA-approved therapy is the first and only GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint.
Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP
Pipeline

Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP

Statistical significance noted for MCO-010 in demonstrating clinically meaningful vision improvement for legally blind, advanced RP patients.
Is lotilaner for Demodex effective at 1 year?
Research

Is lotilaner for Demodex effective at 1 year?

Saturn-1 extension study compares continued safety and efficacy of lotilaner after both 6 and 12 months
Viatris Eye Care Division launches new YouTube channel aimed at fostering dialogue between dry eye patients and ECPs
Products

Viatris Eye Care Division launches new YouTube channel aimed at fostering dialogue between dry eye patients and ECPs

A new YouTube channel is making it easier for eyecare professionals and patients to talk about dry eye disease.
Lenz Therapeutics merges with Graphite Bio
Business

Lenz Therapeutics merges with Graphite Bio

Combined company under LENZ is focusing on advancing two presbyopia therapeutic candidates.
iStent inject with cataract surgery may reduce glaucoma meds
Research

iStent inject with cataract surgery may reduce glaucoma meds

iStent Inject demonstrates clinically and statistically significant reduction in glaucoma medications at 2 years.
Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint
Pipeline

Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint

Intravitreal injection of high-dose IBI302 demonstrates positive long-interval dosing efficacy and safety data.
Study finds Nanodropper Adaptor demonstrates efficacy and safety as glaucoma treatment
Research

Study finds Nanodropper Adaptor demonstrates efficacy and safety as glaucoma treatment

Non-inferiority study evaluates microdrops vs conventional eye drops for lowering IOP.
University of Purdue receives $6.7M grant to advance development of smart contacts
Research

University of Purdue receives $6.7M grant to advance development of smart contacts

Soft contact lenses are designed to provide continuous, 24/7 monitoring of IOP for glaucoma.
AAO weighs in on Congress passing Medicare Physician Payment adjustment
Legal

AAO weighs in on Congress passing Medicare Physician Payment adjustment

Partial funding bill softens the original conversion factor decrease of 3.37% that took effect on Jan. 1, 2024.
Researchers tie DR to cardiovascular disease
Research

Researchers tie DR to cardiovascular disease

New study suggests DR and CVD could potentially act as independent markers of each other.
Clearside Biomedical names retinal industry veteran as CMO
Business

Clearside Biomedical names retinal industry veteran as CMO

Victor Chong, MD, MBA, assumed his new role on March 14.
GenSight Biologics reports 4-year efficacy and safety data on LUMEVOQ for LHON
Pipeline

GenSight Biologics reports 4-year efficacy and safety data on LUMEVOQ for LHON

Latest results confirm 3-year safety and efficacy of one-time injection in unilateral- and bilateral-treated eyes.
Poor sleep duration may lead to POAG
Research

Poor sleep duration may lead to POAG

Study investigates possible association between sleep-related phenotypes and POAG risk.